Eurofins Scientific SE
ERF.PAHealthcareEURONEXTDiagnostics & Research · Last scanned May 30, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Eurofins Scientific SE focuses on Diagnostics & Research services and products. Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The $10.91B market capitalization puts ERF.PA squarely in large-cap range for its industry. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics.
Market Cap
$10.91B
Beta
0.85
P/E (TTM)
24.49
P/E (Fwd)
13.43
EPS (TTM)
$2.55
EPS (Fwd)
$4.65
ROE
9.5%
ROA
5.5%
Cash
$794.2M
Total Debt
$4.43B
Free CF
$492.5M
52W Change
6.3%
Annual Financials
Cash vs Debt
On the balance sheet, ERF.PA has $794.2M in cash with $4.43B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $492.5M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 9.5% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $6.71B (2022) to $7.30B (2025).
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing ERF.PA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.